Engineering Biology to Transform Precision Medicine
SphereBio has developed XSpheres™, therapeutic nanovehicles engineered to precisely deliver complex biological payloads directly inside target cells.
By combining synthetic biology, AI, and advanced nanotechnology, our modular bioplatform overcomes longstanding barriers in intracellular access, opening new frontiers for previously untreatable diseases
Key attributes
Our Science
About 99% of therapeutic molecules taken up by cells become trapped in intracellular compartments and degraded before they can reach their functional target.
At SphereBio we got inspired by viral machinery to design our foundational technology - XSpheres™- non-viral cell-derived nanovehicles modified to act like trojan-horses, entering cells and releasing their cargo inside.
Our lead product, OncoSpheres™️, is a personalized cancer vaccine built using XSpheres™️ produced from a patient's own tumor biopsy. Unlike conventional approaches that pre-select a limited set of tumor signals as targets, OncoSpheres™️ carry almost all the information contained in the patient’s tumor. Delivering more comprehensive tumor information directly inside immune cells is a key factor in generating a broader and more potent immune cell repertoire to recognize and eliminate cancer cells.
Technology Highlights
About SphereBio
Meet the people behind SphereBio
0
+
Years of Reasearch in virology, oncology, and bioinformatics
Culture of Scientific Excelence
Partnership and investment
SphereBio is strategically positioned in the rapidly growing intracellular delivery and the cancer vaccines markets, validated by prestigious collaborations (Brigham and Women’s Hospital, Dana Farber Cancer Hospital, and NYU Langone) and recognized by leading biotech investors and industry leaders.
Collaborations
Engage with SphereBio
Become part of our journey. Connect directly with our leadership team, explore collaborative opportunities, or access detailed investment information.
